🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Lupin Limited LUPIN NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.lupin.com

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

READ MORE ›
₹2,267.70
+15.82% 1Y

Market & Price

Market Cap
₹1.04 L Cr
Current Price
₹2,267.70
High / Low (52W)
₹2,460.10 / ₹1,851.80
Beta
0.23

Valuation

Stock P/E
19.49
Industry PE
37.60
Forward P/E
22.28
PEG Ratio
-
Book Value
₹491.29
Price to Book
4.62
P/S
3.71
EV/EBITDA
12.39
Dividend Yield
0.53%

Profitability & Returns

ROCE
28.42%
ROE
26.91%
ROA
12.76%
Profit Margin
19.07%
Op Margin
24.24%
EPS (Latest Qtr)
₹31.89
EPS (TTM)
₹116.33

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
1.25
Current Ratio
1.90
Debt
₹6,616.18 Cr
Total Assets
₹38,364.83 Cr
Current Assets
₹24,027.38 Cr
Working Capital
₹11,376.14 Cr

Ownership

Promoter Holding
47.03%
Chg in Prom Hold
-
FII / Inst Holding
35.10%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹1.01 L Cr
Total Revenue (TTM)
₹27,958.03 Cr
EBITDA
₹8,159.53 Cr
Free Cash Flow
₹4,926.22 Cr
Operating Cash Flow
₹7,334.50 Cr
Shares Outstanding
₹45.72 Cr
Gross Margin
73.79%
Payout Ratio
10.31%

Growth (CAGR)

Revenue 5Y
19.10%
Profit 5Y
131.46%
Revenue (YoY)
31.90%
Earnings (YoY)
89.00%

PROS

  • Strong return on equity of 26.9%.
  • Healthy ROCE of 28.4%.
  • Compounding revenue at 19.1% over 5 years.
  • Profit CAGR of 131.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 965.10 65.34 ₹93,927.75 Cr 0.16% 12.70% 14.33% 23.10% 9.34%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue -5,618.56 Cr5,562.20 Cr6,163.75 Cr7,100.45 Cr7,391.91 Cr
Cost of Revenue -1,721.55 Cr1,686.20 Cr1,771.93 Cr1,878.13 Cr1,851.63 Cr
Gross Profit -3,897.01 Cr3,876.00 Cr4,391.82 Cr5,222.32 Cr5,540.28 Cr
Operating Expenses -2,802.61 Cr2,977.06 Cr1,163.86 Cr3,325.79 Cr3,816.00 Cr
Operating Income -1,094.40 Cr898.94 Cr3,227.96 Cr1,896.53 Cr1,724.28 Cr
EBITDA -1,409.61 Cr1,378.12 Cr1,692.75 Cr1,949.98 Cr2,494.95 Cr
Interest Expense -66.89 Cr89.10 Cr91.76 Cr114.98 Cr120.16 Cr
Pretax Income -1,071.27 Cr895.84 Cr1,415.54 Cr1,522.04 Cr1,928.00 Cr
Tax Provision -212.41 Cr113.46 Cr194.08 Cr341.53 Cr459.33 Cr
Net Income -855.16 Cr772.52 Cr1,219.03 Cr1,175.55 Cr1,460.34 Cr
Diluted EPS -18.6916.8726.6225.6731.89

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -16,269.98 Cr19,656.34 Cr22,192.11 Cr27,487.54 Cr
Cost of Revenue -7,264.89 Cr7,146.78 Cr6,842.25 Cr7,326.46 Cr
Gross Profit -9,005.09 Cr12,509.56 Cr15,349.86 Cr20,161.08 Cr
Operating Expenses -8,115.65 Cr9,712.92 Cr11,241.60 Cr5,479.54 Cr
Operating Income -889.44 Cr2,796.64 Cr4,108.26 Cr14,681.54 Cr
EBITDA -1,837.39 Cr3,898.12 Cr5,479.13 Cr8,682.54 Cr
Interest Expense -240.21 Cr279.04 Cr294.87 Cr434.49 Cr
Pretax Income -716.49 Cr2,422.27 Cr4,015.00 Cr6,872.55 Cr
Tax Provision -268.80 Cr486.70 Cr708.74 Cr1,517.08 Cr
Net Income -430.08 Cr1,914.48 Cr3,281.62 Cr5,332.84 Cr
Diluted EPS -9.4141.8771.69116.44

Compounded Sales Growth

5 Years:19.10%
1 Year:31.90%

Compounded Profit Growth

5 Years:131.46%
1 Year:89.00%

Stock Price Performance

1 Year:+15.82%
6 Months:+13.41%
3 Months:+1.17%
1 Month:-1.89%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -22,955.93 Cr23,997.18 Cr29,204.88 Cr38,364.83 Cr
Current Assets -12,451.30 Cr13,447.65 Cr16,798.58 Cr24,027.38 Cr
Cash & Equivalents -1,277.82 Cr1,187.60 Cr1,930.78 Cr4,167.73 Cr
Inventory -4,491.76 Cr4,953.90 Cr5,476.35 Cr6,083.25 Cr
Receivables -4,480.70 Cr4,692.05 Cr5,497.10 Cr6,604.06 Cr
Total Liabilities -10,413.11 Cr9,623.73 Cr11,910.53 Cr15,851.46 Cr
Current Liabilities -9,265.37 Cr8,501.50 Cr8,961.39 Cr12,651.24 Cr
Long Term Debt -27.51 Cr01,766.23 Cr1,643.39 Cr
Total Debt -4,541.52 Cr2,921.77 Cr5,447.77 Cr6,616.18 Cr
Total Equity -12,464.50 Cr14,290.29 Cr17,203.50 Cr22,448.27 Cr
Shares Outstanding -45.50 Cr45.57 Cr45.66 Cr45.72 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -1,897.24 Cr3,648.36 Cr2,999.94 Cr7,334.50 Cr
Investing Cash Flow --1,286.77 Cr-1,712.20 Cr-4,171.89 Cr-3,864.59 Cr
Financing Cash Flow --337.25 Cr-2,184.21 Cr1,731.88 Cr-845.87 Cr
Capital Expenditure --1,499.62 Cr-928.90 Cr-1,682.43 Cr-2,054.85 Cr
Free Cash Flow -397.62 Cr2,719.46 Cr1,317.51 Cr5,279.65 Cr
Net Change in Cash -273.22 Cr-248.05 Cr559.93 Cr2,624.04 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -55.3%63.6%69.2%73.3%
Operating Margin % -5.5%14.2%18.5%53.4%
Net Margin % -2.6%9.7%14.8%19.4%
ROE % -3.5%13.4%19.1%23.8%
ROCE % -6.5%18.0%20.3%57.1%

Shareholding Pattern

Insiders
47.03%
Institutions
35.10%
Public Float
66.25%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LUPIN

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space